Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03135327 · ClinicalTrials.gov registry record · NA

Clinical Applications of Advanced Ophthalmic Imaging

A NA study of Multiple Sclerosis and Dementia, sponsored by University of Miami.

Recruiting
Registry status
NA
Development phase
5,000
Enrollment target
1
Study location

NCT03135327 is a NA study of Multiple Sclerosis and Dementia that is actively recruiting participants, run by University of Miami. The registered enrollment target is 5,000 participants, above the 569-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (779% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03135327, a NA study of Multiple Sclerosis and Dementia, is actively recruiting participants, sponsored by University of Miami.

RECRUITING
Registry status
NA
Development phase
5,000 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the clinical application of advanced ophthalmic imaging devices such as optical coherence tomography (OCT), retinal function imager (RFI), slit-lamp biomicroscopy (SLB), PERG in diseased eyes and normal controls. There are two phases in this study. The first phase is an observational phase which studies the eye in various conditions. The second phase is an interventional phase which studies the changes in the eyes after taking an over-the-counter medical food (Ocufolin) for 6 months.

Interventions

  • DIETARY_SUPPLEMENT Ocufolin

Study Locations (1)

Florida

  • Bascom Palmer Eye Institute - Miami

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2007-01-01
Est. Completion 2029-12-31
Phase NA

Sponsor

University of Miami

721 total trials

What the Registry Record Tells You About NCT03135327

The ClinicalTrials.gov registry entry for NCT03135327 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 569-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (779% higher). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Ocufolin is the first listed.

NCT03135327 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT03135327 about?

NCT03135327 is a clinical study titled "Clinical Applications of Advanced Ophthalmic Imaging". The purpose of this study is to determine the clinical application of advanced ophthalmic imaging devices such as optical coherence tomography (OCT), retinal function imager (RFI), slit-lamp biomicroscopy (SLB), PERG in diseased eyes and normal controls. There are two phases in this study. The firs...

What is the current status of trial NCT03135327?

This trial is currently recruiting. It is a NA study. The enrollment target is 5,000 participants. The study started on 2007-01-01. Estimated completion is 2029-12-31.

What conditions does trial NCT03135327 study?

This clinical trial studies the following conditions: Multiple Sclerosis, Dementia, Myopia, Diabetic Retinopathy, Presbyopia.

What interventions are being tested in trial NCT03135327?

The interventions under investigation include: Ocufolin (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03135327?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03135327 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.